OSSIO raises USD 27.6 million 

OSSIO, Inc. recently closed on $27.6 million in equity funding to rapidly scale all aspects of its commercial efforts, including a new product pipeline, sales channel and medical education, as well as building out a flagship U.S. manufacturing site and surgeon training center in Florida.

OSSIOfiber implants provide strong fixation while leaving nothing permanent behind, which avoids the risk of common post-surgical complications and secondary procedures associated with metal and similar materials. After serving their fixation function, they fully integrate and are replaced with the patient’s natural bone.

Questa Capital, which focuses on investments in expansion-stage healthcare companies, led this latest round of financing with participation from existing investors: MVM Partners, OCV, Ortho-Vision and Courage Capital.

“This new investment in OSSIO strengthens our ability to build upon our proven claim as the most innovative and differentiated implant technology to enter the $16 billion orthopedic fixation market,” said OSSIO CEO Brian Verrier. “The additional funding will enable us to accelerate our commercial footprint and the adoption of OSSIOfiber implants in the United States and select international markets. Specifically, we are already expanding our OSSIO sales team to strengthen the support of our distribution partners and customers, as well as securing the needed manufacturing capacity for several years of future growth.”

Since the company’s first product launch in 2019, upwards of 50,000 OSSIOfiber implants have been used across a broad spectrum of orthopedic procedures.

“OSSIO fits squarely into our investment strategy,” said Ryan Drant, Founder and Managing Partner of Questa Capital. “The company is growing rapidly and has established OSSIOfiber implants as a differentiated and disruptive medical technology with clear patient benefits and passionate surgeon users. We are pleased to support OSSIO’s efforts to evolve the practice of orthopedic surgery.”
MB Bureau